Stryker Co. (NYSE:SYK) Stock Position Decreased by Greenwood Capital Associates LLC

Greenwood Capital Associates LLC cut its stake in Stryker Co. (NYSE:SYK) by 0.7% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 22,810 shares of the medical technology company’s stock after selling 154 shares during the period. Stryker accounts for 1.1% of Greenwood Capital Associates LLC’s holdings, making the stock its 24th biggest holding. Greenwood Capital Associates LLC’s holdings in Stryker were worth $8,213,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in the business. Dunhill Financial LLC lifted its holdings in shares of Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares during the last quarter. Darwin Wealth Management LLC purchased a new stake in Stryker in the 3rd quarter worth about $36,000. Crews Bank & Trust purchased a new position in Stryker during the 4th quarter valued at about $39,000. Hara Capital LLC acquired a new position in shares of Stryker in the 3rd quarter valued at about $42,000. Finally, Grove Bank & Trust boosted its holdings in shares of Stryker by 84.8% during the third quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock worth $44,000 after purchasing an additional 56 shares during the period. Institutional investors own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.50% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on SYK shares. UBS Group boosted their price target on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. The Goldman Sachs Group upped their target price on Stryker from $384.00 to $427.00 and gave the stock a “neutral” rating in a research report on Thursday, January 30th. Canaccord Genuity Group lifted their price target on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. StockNews.com downgraded Stryker from a “buy” rating to a “hold” rating in a report on Thursday, January 30th. Finally, Needham & Company LLC restated a “buy” rating and set a $442.00 price target on shares of Stryker in a report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $419.37.

Stryker Trading Down 0.1 %

Shares of SYK opened at $390.59 on Tuesday. The stock’s fifty day simple moving average is $376.68 and its 200-day simple moving average is $363.22. The firm has a market capitalization of $148.90 billion, a PE ratio of 50.40, a price-to-earnings-growth ratio of 2.78 and a beta of 0.96. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the business earned $3.46 earnings per share. As a group, research analysts predict that Stryker Co. will post 13.5 earnings per share for the current year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Tuesday, December 31st were paid a dividend of $0.84 per share. The ex-dividend date of this dividend was Tuesday, December 31st. This is a boost from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.86%. Stryker’s payout ratio is 43.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.